Korean J Pancreas Biliary Tract.  2015 Jan;20(1):5-13. 10.15279/kpba.2015.20.1.5.

Chemotherapy and Targeted Therapy with Management of Related Complications in Pancreatic Cancer

Affiliations
  • 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. lkhyuck@gmail.com

Abstract

Prognosis of pancreatic ductal adenocarcinoma is exceptionally poor because timely diagnosis in resectable stages is rare and there is no curative treatment for unresectable cases. Numerous researches to overcome these obstacles resulted in statistically significant but small progress. Recently two randomized controlled trial reported combination chemotherapy with 5-FU, irinotecan, leucovorin and oxaliplatin or Nab-paclitaxel plus gemcitabine was better survival than gemcitabine monotherapy. Many novel biological agents targeting the pancreatic cancer itself and surrounding micro-environment has been reported to be promising in preclinical investigations and phase 1/2 clinical studies. However, only erlotinib - a small molecular inhibitor of the epidermal growth factor receptor pathway - was approved for the targeted therapy for metastatic pancreatic cancer. In this review, we discuss briefly about recent advances in the combination chemotherapy and the targeted therapy including several complications related with these drugs.

Keyword

Pancreatic cancer; Chemotherapy; Targeted therapy; Gemcitabine; FOLFIRINOX; Erlotinib; Nab-paclitaxel

MeSH Terms

Adenocarcinoma
Biological Factors
Diagnosis
Drug Therapy*
Drug Therapy, Combination
Fluorouracil
Leucovorin
Pancreatic Ducts
Pancreatic Neoplasms*
Prognosis
Receptor, Epidermal Growth Factor
Erlotinib Hydrochloride
Biological Factors
Fluorouracil
Leucovorin
Receptor, Epidermal Growth Factor
Full Text Links
  • KJPBT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error